Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

Xu-Monette, Ziju Y., Xiao, Min, Au, Qingyan, Padmanabhan, Raghav, Xu, Bing, Hoe, Nicholas, Rodríguez-Perales, Sandra, Torres-Ruiz, Raul, Manyam, Ganiraju C., Visco, Carlo, Miao, Yi, Tan, Xiaohong, Zhang, Hongwei, Tzankov, Alexandar, Wang, Jing, Dybkær, Karen, Tam, Wayne, You, Hua, Bhagat, Govind, Hsi, Eric D., Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Piris, Miguel A., van Krieken, J. Han, Winter, Jane N., Westin, Jason R., Pham, Lan V., Medeiros, L. Jeffrey, Rassidakis, George Z., Li, Yong, Freeman, Gordon J., Young, Ken H. · 2019 · Cancer Immunology Research

Abstract

PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types of cancers and are being studied in diffuse large B-cell lymphoma (DLBCL), the most common aggressive B-cell lymphoma. However, whether both PD-1 and CTLA-4 checkpoints are active and clinically significant in DLBCL is unknown. Whether PD-1 ligands expressed by tumor cells or by the microenvironment of DLBCL are critical for the PD-1 immune checkpoint is unclear. We performed immunophenotypic profiling for 405 patients with de novo DLBCL using a MultiOmyx immunofluorescence platform and simultaneously quantitated expression/coexpression of 13 immune markers to identify prognostic determinants. In both training and validation cohorts, results demonstrated a central role of the tumor immune microenvironment, and when its functionality was impaired by deficiency in tumor-infiltrating T cells and/or natural killer cells, high PD-1 expression (but not CTLA-4) on CD8+ T cells, or PD-L1 expression on T cells and macrophages, patients had significantly poorer survival after rituximab–CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) immunochemotherapy. In contrast, tumor-cell PD-L2 expression was associated with superior survival, as well as PD-L1+CD20+ cells proximal (indicates interaction) to PD-1+CD8+ T cells in patients with low PD-1+ percentage of CD8+ T cells. Gene-expression profiling results suggested the reversibility of T-cell exhaustion in PD-1+/PD-L1+ patients with unfavorable prognosis and implication of LILRA/B, IDO1, CHI3L1, and SOD2 upregulation in the microenvironment dysfunction with PD-L1 expression. This study comprehensively characterized the DLBCL immune landscape, deciphered the differential roles of various checkpoint components in rituximab–CHOP resistance in DLBCL patients, and suggests targets for PD-1/PD-L1 blockade and combination immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0439

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 164

Metadata

Authors
Xu-Monette, Z. Y., Xiao, M., Au, Q., Padmanabhan, R., Xu, B., Hoe, N., Rodríguez-Perales, S., Torres-Ruiz, R., Manyam, G. C., Visco, C., Miao, Y., Tan, X., Zhang, H., Tzankov, A., Wang, J., Dybkær, K., Tam, W., You, H., Bhagat, G., Hsi, E. D., Ponzoni, M., Ferreri, A. J. M., Møller, M. B., Piris, M. A., van Krieken, J. H., Winter, J. N., Westin, J. R., Pham, L. V., Medeiros, L. J., Rassidakis, G. Z., Li, Y., Freeman, G. J., & Young, K. H.
Venue
Cancer Immunology Research
Published
2019-04-01
Volume
7
Issue
4
Pages
644-657
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2911487711
Cited by
164
References
9
FWCI
11.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0439
The paper
Xu-Monette, Z. Y., Xiao, M., Au, Q., Padmanabhan, R., Xu, B., Hoe, N., Rodríguez-Perales, S., Torres-Ruiz, R., Manyam, G. C., Visco, C., Miao, Y., Tan, X., Zhang, H., Tzankov, A., Wang, J., Dybkær, K., Tam, W., You, H., Bhagat, G., . . . Young, K. H. (2019). Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0439

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.